对于与癌症相关的缓解癌症的卡诺索尔衍生物的合成,结构-活性关系
Juan Wang1, Qiang Wang1, Kun Wei1
1College of Chemical Engineering, Sichuan University of Science & Engineering, Zigong 643000, Sichuan, PR China.
Bioorganic & medicinal chemistry letters
|September 29, 2025
概括
研究人员开发了一种新化合物,10,通过减少肌肉损失和代谢问题来对抗癌症缓解. 这种carnosol的衍生物显示出作为癌症患者稳定的治疗剂的希望.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 癌症缓解症的特点是肌肉缩和代谢功能障碍,这构成了重大的临床挑战.
- 卡诺索尔是一种天然化合物,具有代谢不稳定性,限制了其治疗潜力.
研究的目的:
- 设计和识别代谢稳定的肉醇衍生物,用于治疗癌症缓解症.
- 为了评估在癌症缓解症的临床前模型中优化卡诺索尔衍生物的疗效.
主要方法:
- 合成了35种卡诺索尔衍生物,用氧化易发生的基组与醇或基基组进行修改.
- 进行结构-活性关系 (SAR) 研究以确定化合物.
- 在C26瘤受条件的细胞模型和C26瘤携带的小鼠模型中评估化合物的疗效.
- 进行药理动力学研究以确定化合物的稳定性和生物可用性.
主要成果:
- 化合物10被确定为衍生物.
- 在体外,化合物10逆转了神经管缩67.08%并减少了脂肪细胞脂解.
- 在体内,复合物10减轻了瘤携带小鼠的缩相关的体重减轻,而不会影响瘤生长.
- 药理动力学分析显示,化合物10具有增强的稳定性,半衰期为11.1小时,AUC0-t为8369 ng/mL.
结论:
- 化合物10是一种有前途的治疗候选药物,用于治疗癌症缓解症.
- 理性设计策略为优化其他自然产品提供了一个框架.
- 化合物10的增强代谢稳定性和疗效需要进一步的临床研究.
更多相关视频
05:17Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay
Published on: February 9, 2021
1.9K
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
19.1K
相关概念视频
01:28Structure-Activity Relationships and Drug Design
1.7K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.7K
02:49Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.8K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.8K
01:21Cancer Survival Analysis
648
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
648
01:25Mutagenicity and Carcinogenicity
1.9K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.9K
01:29Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
2.7K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.7K